 |
|
|
| |
Interim Sustained Virologic Response (SVR), Safety And Tolerability Results Of 8-Week Treatment With ACH-3102 And Sofosbuvir In Chronic Hepatitis C (HCV), Genotype-1 (GT-1), Treatment-Naïve Patients: A Phase 2 "Proxy" Study
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
AUTHORS: Edward Gane1, Hetal Kocinsky2, Christian Schwabe3, Michael Mader2, Vithika Suri3, Mary Donohue2, Mingjun Huang2, James Hui2, Joanna Yang2, Heather Robison2, David Apelian2
AFFILIATIONS: 1New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand, 2Achillion Pharmaceuticals, New Haven, CT, USA, 3Auckland Clinical Studies Ltd, Grafton, New Zealand
|
| |
|
|
|
|
|
